| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(1 year, 5 months ago) | |
| US8106183 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47301 | ASTELLAS | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Feb, 2027
(3 years from now) | |
Lexiscan is owned by Astellas.
Lexiscan contains Regadenoson.
Lexiscan has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Lexiscan are:
- US6403567
Lexiscan was authorised for market use on 10 April, 2008.
Lexiscan is available in solution;intravenous dosage forms.
Lexiscan can be used as method for stimulating coronary vasodilation for purposes of imaging the heart.
The generics of Lexiscan are possible to be released after 02 February, 2027.
Drugs and Companies using REGADENOSON ingredient
Market Authorisation Date: 10 April, 2008
Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart
Dosage: SOLUTION;INTRAVENOUS
LEXISCAN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic